The Corvidia Pipeline

Pipeline

Our pipeline is currently focused on treating the life-threatening conditions of 1) atherosclerotic cardiovascular disease (ASCVD) and inflammation in patients with chronic kidney disease (CKD), and 2) high triglyceride-induced Acute Pancreatitis (AP).
Ziltivekimab

We are developing ziltivekimab to potentially be the first therapy intended to reduce the risk of major cardiovascular adverse events in patients with chronic kidney disease (CKD) who have atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients in the United States who are diagnosed with moderate to severe CKD may have ASCVD and inflammation. These patients are at increased risk for an adverse cardiovascular event and there are no approved therapies to prevent this risk.

The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated across human genetic studies and preclinical studies. CANTOS, a major outcomes study published in 2017, evaluated an anti-IL1b drug that targets the same pathway as ziltivekimab in 10,000 patients. CANTOS supports our theory that reducing IL-6 could result in a significant cardiovascular benefit, specifically for patients who have reduced kidney function.

Ziltivekimab, an investigational drug, is in an ongoing Phase 2b clinical trial designed to identify the appropriate dose in order to optimize the efficacy-safety profile for patients.

COR-003

We are developing COR-003 to rapidly reduce triglycerides in hospitalized patients presenting with high-triglyceride-induced acute pancreatitis (AP). High triglycerides are the third leading cause of AP. In the United States, there are an estimated 10,000 to 20,000 hospitalized cases of high triglyceride-induced AP each year¹ and there are currently no approved therapies available for its treatment.

COR-003 is an investigational therapy designed to clear triglycerides from the blood stream in two ways: it acts as the protein coding gene called apolipoprotein C2 (ApoC2) to enhance the LPL enzyme’s ability to clear triglycerides from the blood, and it works against the protein coding gene apolipoprotein C3 (ApoC3) to allow for clearance of triglycerides. COR-003 is in pre-clinical testing.

_____________________
¹ Nils Ewald (2013) Hypertriglyceridemia-induced acute pancreatitis, Clinical Lipidology, 8:5, 587-594
Ziltivekimab
COR-003
New Entrants
PreclinicalPhase 1Phase 2Phase 3

Clinical Trials

Patients are at the center of Corvidia Therapeutics’ mission of discovering, developing and delivering innovative medicines that address significant medical needs. Our goal at Corvidia is to determine whether our investigational medicines are safe and effective and, if so, to advance them through the clinical trial and regulatory process as quickly and responsibly as possible. It is through clinical trials and the successful registration of our medicines with global health authorities that we will be able to make our potential medicines available to the greatest number of patients who might benefit. Learn more.